Navigation Links
Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.'s Fourth Investor Tour of China
Date:4/1/2008

NANJING, China, April 1, 2008 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced its participation in Brean Murray, Carret & Co.'s Fourth Investor Tour of China being held from Monday, March 31, 2008 to Friday, April 4, 2008 in Beijing, Shenzhen and Shanghai.

Simcere's Chief Financial Officer Frank Zhao, will present in the Aries Boardroom of the Grand Hyatt Shanghai on Friday April 4, 2008 at 11:15 am Beijing/Hong Kong time.

A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first- to-market generic and innovative pharmaceuticals, and has introduced a first- to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication, and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases, and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For investor and media inquiries, please contact:

Email: ir@simcere.com

In Nanjing:

Frank Zhao

Chief Financial Officer

Simcere Pharmaceutical

Tel: +86-25-8556-6666 x8818

In Beijing:

Wu Kejia

Brunswick Group

Tel: +86-10-6566-2256

In Hong Kong:

Joseph Lo

Brunswick Group

Tel: +852-3512-5000

In the United States:

Michael Guerin

Brunswick Group LLC

Tel: +1-212-333-3810


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
2. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
3. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
4. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
5. Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
6. Pharmaceutical Strategic Initiatives Adds Anne Sexton, MD, MS to Management Team
7. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
8. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
9. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
10. Barr Pharmaceuticals, Inc. Executive Bios
11. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: